Key Points
-
UnitedHealth recently raised its 2026 adjusted earnings guidance for the third time this year, to at least $20.50 per share.
-
Raising premiums, cutting certain benefits, and exiting less profitable markets lifted UnitedHealth’s health insurance operating margin to 3.3%.
-
Optum has restructured operations and exited less attractive contracts, while automation and AI could streamline administration in its technology business.
-
UnitedHealth Group (NYSE: UNH) may finally be turning a corner after a difficult stretch. These days, with management repeatedly raising earnings guidance (most recently on Oct. 13) and profitability showing signs of recovery, could the healthcare giant be poised for a comeback?
Here’s what a $10,000 investment could become if the turnaround holds.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
UnitedHealth is finally putting its turnaround into action
For much of the past two years, UnitedHealth has struggled to convince investors it could turn its business around. But that picture is starting to change. In fact, UnitedHealth has now raised its full-year earnings guidance three times in 2026.
Its latest third-quarter results offered another encouraging sign that management’s efforts are starting to pay off. Specifically, the company reported adjusted earnings of $4.69 per share, compared with $2.92 in the same quarter last year. But more importantly, management raised its full-year 2026 adjusted earnings outlook to at least $20.50 per share, up from its previous range of between $19.50 and $20.00.
Still, for investors, the bigger question now is whether these improvements represent a temporary rebound or the beginning of a more sustainable recovery. So far, the latest results have given more reasons to be optimistic.
Medicare Advantage is becoming a strong earnings driver
One of UnitedHealth’s biggest challenges has been rising medical costs across its insurance business, particularly in Medicare Advantage. In response, the company had to begin making big changes to the business. These included raising premiums, reducing certain benefits, and exiting less profitable markets.
The strategy meant sacrificing short-term membership growth, but the results suggest that this new approach is working. In fact, in the third quarter, the health insurance segment generated $2.8 billion in operating earnings, compared with $1.8 billion a year earlier. Plus, its operating margin improved to 3.3% from 2.1%.
Looking ahead, management sees opportunities to further improve its Medicare Advantage business in 2027. Specifically, the company is focusing on markets and products where it believes it can achieve more durable margins, including special needs plans for seniors with more complex healthcare needs.
Meanwhile, UnitedHealth’s healthcare services business is turning into a strong growth driver.
Optum could become another major growth catalyst
Perhaps one of UnitedHealth’s most important competitive advantages comes from Optum, which operates across healthcare delivery, pharmacy services, and technology segments. This diversification is valuable as the healthcare industry looks for ways to trim costs, improve efficiency, and coordinate healthcare.
There is an additional long-term opportunity in Optum’s technology operations. For example, automation and artificial intelligence (AI) could help streamline administrative processes and improve the way patients and providers interact with the healthcare system.
All told, if existing operations continue to recover and productivity improvements from automation and AI materialize, UnitedHealth would be better positioned to deliver stronger earnings growth. That raises the question of what stronger earnings growth could mean for investors.
The turnaround could reward patient investors
Ultimately, if the company executes its turnaround plans well, investors could be rewarded. To illustrate, starting with its 2026 adjusted earnings per share (EPS) projection of at least $20.50 and applying the low end of management’s long-term earnings growth target of 13%-16%, adjusted EPS could reach around $23.17 in 2027.
From there, applying a 22 price-to-earnings (P/E) ratio produces a price target of around $510 per share, which would turn a $10,000 investment into about $12,400.
In the table below, I used a base case assuming 14.5% growth and a slightly higher 23 P/E, and a bull case using the upper end of growth and a 24 multiple.
| Scenario |
2027 EPS growth |
2027 adjusted EPS |
P/E multiple |
Target price |
Upside vs. $412.02 last close |
$10,000 could become |
| Conservative |
13% |
$23.17 |
22 |
$510 |
24% |
$12,400 |
| Base |
14.5% |
$23.47 |
23 |
$540 |
31% |
$13,100 |
| Bull |
16% |
$23.78 |
24 |
$571 |
39% |
$13,900 |
Data source: Calculations by the author.
Overall, if management can sustain the turnaround and restore profitability across the company, investors could be looking at a much stronger investment case in the years ahead.
Should you buy stock in UnitedHealth Group right now?
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 17, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.